Cargando…
Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial
BACKGROUND AND AIMS: The clinical efficacy of fecal microbiota transplantation (FMT) in patients with non-alcoholic fatty liver disease (NAFLD) and the variant effects of FMT on lean and obese NAFLD patients remain elusive. Our study aimed to determine the clinical efficacy and safety of FMT for pat...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289257/ https://www.ncbi.nlm.nih.gov/pubmed/35860380 http://dx.doi.org/10.3389/fcimb.2022.759306 |
_version_ | 1784748624380428288 |
---|---|
author | Xue, Lanfeng Deng, Zhiliang Luo, Wenhui He, Xingxiang Chen, Yu |
author_facet | Xue, Lanfeng Deng, Zhiliang Luo, Wenhui He, Xingxiang Chen, Yu |
author_sort | Xue, Lanfeng |
collection | PubMed |
description | BACKGROUND AND AIMS: The clinical efficacy of fecal microbiota transplantation (FMT) in patients with non-alcoholic fatty liver disease (NAFLD) and the variant effects of FMT on lean and obese NAFLD patients remain elusive. Our study aimed to determine the clinical efficacy and safety of FMT for patients with NAFLD, elucidating its different influences on lean and obese patients with NAFLD. METHODS: We performed a randomized and controlled clinical trial. Patients in the non-FMT group were administered oral probiotics. In the FMT group, patients were randomized to receive FMT with donor stool (heterologous) via colonoscopy, followed by three enemas over 3 days. Both groups were also required to maintain a healthy diet and keep regular exercise for more than 40 min every day. They returned to the hospital for reexamination 1 month after treatment. RESULTS: FMT can decrease the fat accumulation in the liver by improving the gut microbiota dysbiosis, thus attenuating fatty liver disease. Significant differences in the clinical features and gut microbiota between lean and obese NAFLD patients were unveiled. Moreover, FMT had better effects on gut microbiota reconstruction in lean NAFLD than in obese NAFLD patients. CONCLUSIONS: FMT could successfully improve the therapeutic effects on patients with NAFLD, and its clinical efficacy was higher in lean NAFLD than in obese NAFLD patients. |
format | Online Article Text |
id | pubmed-9289257 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92892572022-07-19 Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial Xue, Lanfeng Deng, Zhiliang Luo, Wenhui He, Xingxiang Chen, Yu Front Cell Infect Microbiol Cellular and Infection Microbiology BACKGROUND AND AIMS: The clinical efficacy of fecal microbiota transplantation (FMT) in patients with non-alcoholic fatty liver disease (NAFLD) and the variant effects of FMT on lean and obese NAFLD patients remain elusive. Our study aimed to determine the clinical efficacy and safety of FMT for patients with NAFLD, elucidating its different influences on lean and obese patients with NAFLD. METHODS: We performed a randomized and controlled clinical trial. Patients in the non-FMT group were administered oral probiotics. In the FMT group, patients were randomized to receive FMT with donor stool (heterologous) via colonoscopy, followed by three enemas over 3 days. Both groups were also required to maintain a healthy diet and keep regular exercise for more than 40 min every day. They returned to the hospital for reexamination 1 month after treatment. RESULTS: FMT can decrease the fat accumulation in the liver by improving the gut microbiota dysbiosis, thus attenuating fatty liver disease. Significant differences in the clinical features and gut microbiota between lean and obese NAFLD patients were unveiled. Moreover, FMT had better effects on gut microbiota reconstruction in lean NAFLD than in obese NAFLD patients. CONCLUSIONS: FMT could successfully improve the therapeutic effects on patients with NAFLD, and its clinical efficacy was higher in lean NAFLD than in obese NAFLD patients. Frontiers Media S.A. 2022-07-04 /pmc/articles/PMC9289257/ /pubmed/35860380 http://dx.doi.org/10.3389/fcimb.2022.759306 Text en Copyright © 2022 Xue, Deng, Luo, He and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Xue, Lanfeng Deng, Zhiliang Luo, Wenhui He, Xingxiang Chen, Yu Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial |
title | Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial |
title_full | Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial |
title_fullStr | Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial |
title_full_unstemmed | Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial |
title_short | Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial |
title_sort | effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289257/ https://www.ncbi.nlm.nih.gov/pubmed/35860380 http://dx.doi.org/10.3389/fcimb.2022.759306 |
work_keys_str_mv | AT xuelanfeng effectoffecalmicrobiotatransplantationonnonalcoholicfattyliverdiseasearandomizedclinicaltrial AT dengzhiliang effectoffecalmicrobiotatransplantationonnonalcoholicfattyliverdiseasearandomizedclinicaltrial AT luowenhui effectoffecalmicrobiotatransplantationonnonalcoholicfattyliverdiseasearandomizedclinicaltrial AT hexingxiang effectoffecalmicrobiotatransplantationonnonalcoholicfattyliverdiseasearandomizedclinicaltrial AT chenyu effectoffecalmicrobiotatransplantationonnonalcoholicfattyliverdiseasearandomizedclinicaltrial |